Recursion Pharmaceuticals (RXRX) Competitors $6.04 -0.23 (-3.67%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RXRX vs. SDGR, RCUS, RLAY, ABCL, SWTX, ELAN, BPMC, LNTH, NUVL, and CYTKShould you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Schrödinger (SDGR), Arcus Biosciences (RCUS), Relay Therapeutics (RLAY), AbCellera Biologics (ABCL), SpringWorks Therapeutics (SWTX), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Lantheus (LNTH), Nuvalent (NUVL), and Cytokinetics (CYTK). These companies are all part of the "medical" sector. Recursion Pharmaceuticals vs. Schrödinger Arcus Biosciences Relay Therapeutics AbCellera Biologics SpringWorks Therapeutics Elanco Animal Health Blueprint Medicines Lantheus Nuvalent Cytokinetics Recursion Pharmaceuticals (NASDAQ:RXRX) and Schrödinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, community ranking, risk, valuation, dividends, earnings and analyst recommendations. Does the MarketBeat Community favor RXRX or SDGR? Schrödinger received 26 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 56.99% of users gave Schrödinger an outperform vote while only 55.10% of users gave Recursion Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRecursion PharmaceuticalsOutperform Votes2755.10% Underperform Votes2244.90% SchrödingerOutperform Votes5356.99% Underperform Votes4043.01% Do analysts rate RXRX or SDGR? Recursion Pharmaceuticals currently has a consensus target price of $9.25, indicating a potential upside of 53.15%. Schrödinger has a consensus target price of $32.90, indicating a potential upside of 71.62%. Given Schrödinger's stronger consensus rating and higher probable upside, analysts plainly believe Schrödinger is more favorable than Recursion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Recursion Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Schrödinger 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.82 Is RXRX or SDGR more profitable? Schrödinger has a net margin of -91.84% compared to Recursion Pharmaceuticals' net margin of -579.52%. Schrödinger's return on equity of -35.77% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Recursion Pharmaceuticals-579.52% -76.56% -55.68% Schrödinger -91.84%-35.77%-24.51% Do insiders & institutionals believe in RXRX or SDGR? 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.1% of Schrödinger shares are owned by institutional investors. 15.8% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 8.6% of Schrödinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer RXRX or SDGR? In the previous week, Recursion Pharmaceuticals had 1 more articles in the media than Schrödinger. MarketBeat recorded 11 mentions for Recursion Pharmaceuticals and 10 mentions for Schrödinger. Schrödinger's average media sentiment score of 0.47 beat Recursion Pharmaceuticals' score of 0.13 indicating that Schrödinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Schrödinger 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation and earnings, RXRX or SDGR? Schrödinger has higher revenue and earnings than Recursion Pharmaceuticals. Schrödinger is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRecursion Pharmaceuticals$44.58M38.84-$328.07M-$1.53-3.95Schrödinger$216.67M6.44$40.72M-$2.34-8.19 Which has more risk & volatility, RXRX or SDGR? Recursion Pharmaceuticals has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. SummarySchrödinger beats Recursion Pharmaceuticals on 13 of the 19 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXRX vs. The Competition Export to ExcelMetricRecursion PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.80B$2.93B$5.01B$8.81BDividend YieldN/A1.89%5.16%4.06%P/E Ratio-3.9545.25134.3717.77Price / Sales38.84360.241,158.6875.18Price / CashN/A160.0933.5332.53Price / Book3.303.734.674.68Net Income-$328.07M-$41.63M$119.07M$226.08M7 Day Performance-12.59%-4.73%-1.83%-1.04%1 Month Performance-10.65%-6.53%-3.62%1.04%1 Year Performance-7.65%25.63%31.63%26.28% Recursion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXRXRecursion Pharmaceuticals1.9932 of 5 stars$6.04-3.7%$9.25+53.1%-12.0%$1.80B$44.58M-3.95400Analyst ForecastOptions VolumeHigh Trading VolumeSDGRSchrödinger1.9918 of 5 stars$19.17+1.3%$32.90+71.6%-37.1%$1.38B$216.67M0.00867RCUSArcus Biosciences2.677 of 5 stars$14.62+0.8%$34.00+132.6%+4.7%$1.33B$117M0.00500RLAYRelay Therapeutics3.2705 of 5 stars$4.66-2.9%$21.22+355.4%-44.5%$803.44M$25.55M0.00304Gap DownHigh Trading VolumeABCLAbCellera Biologics2.9951 of 5 stars$2.67-1.5%$8.67+224.6%-42.0%$788.64M$38.03M-4.38586Positive NewsSWTXSpringWorks Therapeutics2.0431 of 5 stars$37.44-1.3%$67.00+79.0%+68.5%$2.82B$5.45M0.00305Analyst ForecastELANElanco Animal Health4.1102 of 5 stars$13.44+1.0%$17.14+27.6%+13.1%$6.64B$4.42B33.609,300BPMCBlueprint Medicines2.7079 of 5 stars$94.81+0.2%$122.11+28.8%+43.9%$6.02B$249.38M-44.93640Analyst ForecastLNTHLantheus4.5262 of 5 stars$86.45+8.8%$122.50+41.7%+25.1%$6.01B$1.30B14.38834Positive NewsGap UpNUVLNuvalent2.1677 of 5 stars$91.17+0.1%$112.60+23.5%+51.1%$5.90BN/A0.0040CYTKCytokinetics3.8052 of 5 stars$49.86-2.4%$83.67+67.8%+54.3%$5.88B$3.22M-9.27250Analyst ForecastInsider TradeOptions VolumeNews Coverage Related Companies and Tools Related Companies Schrödinger Competitors Arcus Biosciences Competitors Relay Therapeutics Competitors AbCellera Biologics Competitors SpringWorks Therapeutics Competitors Elanco Animal Health Competitors Blueprint Medicines Competitors Lantheus Competitors Nuvalent Competitors Cytokinetics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RXRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
